EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Obesity and chronic kidney disease: A current review

Saira Nawaz, Rajkumar Chinnadurai, Saif Al-Chalabi iD, Philip Evans, Philip A Kalra, Akheel A Syed iD, Smeeta Sinha

Obesity Science & Practice · 2023-04 · 9 (2) · 61-74

DOI: 10.1002/osp4.629 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Obesity Science & Practice, online erschienen am 19.07.2022. Verfasst von Saira Nawaz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Biology, Medicine and Health University of Manchester Manchester UK. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity poses significant challenges to healthcare globally, particularly through its bi‐directional relationship with co‐morbid metabolic conditions such as type 2 diabetes and hypertension. There is also emerging evidence of an association between obesity and chronic kidney disease (CKD) which is less well characterized.

Methods

A literature search of electronic libraries was conducted to identify and present a narrative review of the interplay between obesity and CKD.

Findings

Obesity may predispose to CKD directly as it is linked to the histopathological finding of obesity‐related glomerulopathy and indirectly through its widely recognized complications such as atherosclerosis, hypertension, and type 2 diabetes. The biochemical and endocrine products of adipose tissue contribute to pathophysiological processes such as inflammation, oxidative stress, endothelial dysfunction, and proteinuria. The prevention and management of obesity may prove critical in counteracting both the development and advancement of CKD. Moreover, measures of abdominal adiposity such as waist circumference, are generally associated with worse morbidity and mortality in individuals receiving maintenance hemodialysis.

Conclusion

Obesity is a risk factor for the onset and progression of CKD and should be recognized as a potential target for a preventative public health approach to reduce CKD rates within the general population. Future research should focus on the use of glucagon‐like peptide‐1 receptor agonists and sodium–glucose cotransporter 2 inhibitors in patients with CKD and obesity due to their multi‐faceted actions on major outcomes.

Schlagwörter

Stichwörter der Autor:innen

chronic kidney diseasedialysisobesitytransplantation

Autor:innen und Institutionen

  • Faculty of Biology, Medicine and Health University of Manchester Manchester UK.
  • Department of Renal Medicine Salford Royal Hospital Northern Care Alliance NHS Foundation Trust Salford UK.
  • Department of Renal Medicine Liverpool University Hospitals NHS Foundation Trust Liverpool UK.
  • Department of Diabetes, Endocrinology and Obesity Medicine Salford Royal Hospital Northern Care Alliance NHS Foundation Trust Salford UK.

ORCID-Profile: Saif Al-Chalabi, Akheel A Syed

Zitieren

APA

Nawaz, S., Chinnadurai, R., Al-Chalabi, S., Evans, P., Kalra, P. A., Syed, A. A., & Sinha, S. (2023). Obesity and chronic kidney disease: A current review. Obesity Science & Practice, 9(2), 61-74. https://doi.org/10.1002/osp4.629

Vancouver

Nawaz S, Chinnadurai R, Al-Chalabi S, Evans P, Kalra PA, Syed AA, et al. Obesity and chronic kidney disease: A current review. Obesity Science & Practice. 2023;9(2):61-74. doi:10.1002/osp4.629

BibTeX
@article{Nawaz2023,
  author = {Nawaz, Saira and Chinnadurai, Rajkumar and Al-Chalabi, Saif and Evans, Philip and Kalra, Philip A and Syed, Akheel A and Sinha, Smeeta},
  title = {Obesity and chronic kidney disease: A current review},
  journal = {Obesity Science & Practice},
  year = {2023},
  volume = {9},
  number = {2},
  pages = {61--74},
  doi = {10.1002/osp4.629}
}
Kostenlos starten →